Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2016

Description: Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2016

Summary

‘Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2016’, provides an overview of the Gastrointestinal Stromal Tumor (GIST) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST)
- The report reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Gastrointestinal Stromal Tumor (GIST) therapeutics and enlists all their major and minor projects
- The report assesses Gastrointestinal Stromal Tumor (GIST) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

List of Tables
List of Figures
Introduction
Report Coverage
Gastrointestinal Stromal Tumor (GIST) Overview
Therapeutics Development
Pipeline Products for Gastrointestinal Stromal Tumor (GIST) - Overview
Pipeline Products for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis
Gastrointestinal Stromal Tumor (GIST) - Therapeutics under Development by Companies
Gastrointestinal Stromal Tumor (GIST) - Therapeutics under Investigation by Universities/Institutes
Gastrointestinal Stromal Tumor (GIST) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Gastrointestinal Stromal Tumor (GIST) - Products under Development by Companies
Gastrointestinal Stromal Tumor (GIST) - Products under Investigation by Universities/Institutes
Gastrointestinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development
AB Science SA
Advenchen Laboratories, LLC
Ariad Pharmaceuticals, Inc.
Arog Pharmaceuticals, Inc.
Array BioPharma Inc.
Astex Pharmaceuticals, Inc.
Blueprint Medicines Corporation
Boston Biomedical, Inc.
Calithera Biosciences, Inc.
Chipscreen Biosciences Ltd
Mechanism of Action
R&D Progress
DCC-2618 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
evofosfamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
infigratinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interferon gamma-1b - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Intuvax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KTN-0158 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
masitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nilotinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NMSP-088 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NRCAN-019 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
onalespib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pexidartinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PLX-9486 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ponatinib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SF-1126 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SHR-1020 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize GPR20 for Gastro-Intestinal Stromal Tumors and Acute Myeloid Leukemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TGR-1202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vemurafenib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gastrointestinal Stromal Tumor (GIST) - Recent Pipeline Updates
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects
Gastrointestinal Stromal Tumor (GIST) - Discontinued Products
Gastrointestinal Stromal Tumor (GIST) - Product Development Milestones
Featured News & Press Releases
Apr 20, 2016: Kolltan Pharmaceuticals Announces Presentations of Anti-KIT Antibody Preclinical Data at the 2016 American Association for Cancer Research Annual Meeting
Jul 13, 2015: Blueprint Medicines Receives FDA Authorization to Proceed with Clinical Trials for BLU-285
Apr 19, 2015: Blueprint Medicines Presents New Preclinical Data Demonstrating Significant Anti-Tumor Activity of BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets
Apr 08, 2015: Blueprint Medicines to Present New Preclinical Data on BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets at Upcoming AACR Annual Meeting
Jun 01, 2014: ARIAD Announces Initial Data from Phase 2 Trial of Ponatinib in Patients with Gastrointestinal Stromal Tumors
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Astex Pharmaceuticals, Inc., H1 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Blueprint Medicines Corporation, H1 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Boston Biomedical, Inc., H1 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Calithera Biosciences, Inc., H1 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Chipscreen Biosciences Ltd, H1 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Horizon Pharma Plc, H1 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Immunicum AB, H1 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Natco Pharma Limited, H1 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Nerviano Medical Sciences S.r.l., H1 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Novartis AG, H1 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Omeros Corporation, H1 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Plexxikon Inc., H1 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by TG Therapeutics, Inc., H1 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Gastrointestinal Stromal Tumor (GIST) Therapeutics - Recent Pipeline Updates, H1 2016
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H1 2016
Gastrointestinal Stromal Tumor (GIST) - Discontinued Products, H1 2016
List of Figures
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H1 2016
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3746954/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3746954/
Office Code: SCD2I6NX

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  
Mr [ ]  Mrs [ ]  Dr [ ]  Miss [ ]  Ms [ ]  Prof [ ]

First Name: ___________________________  Last Name: ___________________________

Email Address: * ___________________________

Job Title: ___________________________

Organisation: ___________________________

Address: ___________________________

City: ___________________________

Postal / Zip Code: ___________________________

Country: ___________________________

Phone Number: ___________________________

Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World